Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 7.21
BLUE's Cash-to-Debt is ranked lower than
59% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. BLUE: 7.21 )
Ranked among companies with meaningful Cash-to-Debt only.
BLUE' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.3  Med: No Debt Max: No Debt
Current: 7.21
4.3
No Debt
Equity-to-Asset 0.84
BLUE's Equity-to-Asset is ranked higher than
76% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. BLUE: 0.84 )
Ranked among companies with meaningful Equity-to-Asset only.
BLUE' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.8  Med: 0.8 Max: 0.92
Current: 0.84
-0.8
0.92
Debt-to-Equity 0.10
BLUE's Debt-to-Equity is ranked higher than
73% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. BLUE: 0.10 )
Ranked among companies with meaningful Debt-to-Equity only.
BLUE' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05  Med: 0.11 Max: 0.18
Current: 0.1
0.05
0.18
Debt-to-EBITDA -0.43
BLUE's Debt-to-EBITDA is ranked lower than
99.99% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. BLUE: -0.43 )
Ranked among companies with meaningful Debt-to-EBITDA only.
BLUE' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.49  Med: -0.47 Max: -0.38
Current: -0.43
-0.49
-0.38
Piotroski F-Score: 4
Altman Z-Score: 17.71
Beneish M-Score: -0.53
WACC vs ROIC
19.64%
-84.30%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -850.42
BLUE's Operating Margin % is ranked lower than
76% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. BLUE: -850.42 )
Ranked among companies with meaningful Operating Margin % only.
BLUE' s Operating Margin % Range Over the Past 10 Years
Min: -6975.29  Med: -1200.63 Max: -123.62
Current: -850.42
-6975.29
-123.62
Net Margin % -857.55
BLUE's Net Margin % is ranked lower than
76% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. BLUE: -857.55 )
Ranked among companies with meaningful Net Margin % only.
BLUE' s Net Margin % Range Over the Past 10 Years
Min: -6961.76  Med: -1184.62 Max: -125.47
Current: -857.55
-6961.76
-125.47
ROE % -30.08
BLUE's ROE % is ranked higher than
56% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. BLUE: -30.08 )
Ranked among companies with meaningful ROE % only.
BLUE' s ROE % Range Over the Past 10 Years
Min: -52.8  Med: -26.93 Max: -15.15
Current: -30.08
-52.8
-15.15
ROA % -24.80
BLUE's ROA % is ranked higher than
56% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. BLUE: -24.80 )
Ranked among companies with meaningful ROA % only.
BLUE' s ROA % Range Over the Past 10 Years
Min: -50.45  Med: -22.24 Max: -12.47
Current: -24.8
-50.45
-12.47
ROC (Joel Greenblatt) % -199.76
BLUE's ROC (Joel Greenblatt) % is ranked higher than
60% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. BLUE: -199.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BLUE' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2352.78  Med: -408.7 Max: -186.32
Current: -199.76
-2352.78
-186.32
3-Year Revenue Growth Rate -5.30
BLUE's 3-Year Revenue Growth Rate is ranked lower than
62% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. BLUE: -5.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BLUE' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -53.2  Med: -40.7 Max: -5.3
Current: -5.3
-53.2
-5.3
3-Year EBITDA Growth Rate -51.00
BLUE's 3-Year EBITDA Growth Rate is ranked lower than
88% of the 722 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. BLUE: -51.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BLUE' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -53.6  Med: 5.8 Max: 74.2
Current: -51
-53.6
74.2
3-Year EPS without NRI Growth Rate -61.50
BLUE's 3-Year EPS without NRI Growth Rate is ranked lower than
92% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. BLUE: -61.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BLUE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -61.5  Med: -11.1 Max: 78
Current: -61.5
-61.5
78
GuruFocus has detected 3 Warning Signs with bluebird bio Inc BLUE.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BLUE's 30-Y Financials

Financials (Next Earnings Date: 2018-08-02)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

BLUE Guru Trades in Q2 2017

Joel Greenblatt 12,687 sh (New)
Paul Tudor Jones 4,149 sh (New)
Leon Cooperman 50,000 sh (New)
» More
Q3 2017

BLUE Guru Trades in Q3 2017

Jim Simons 78,800 sh (New)
Vanguard Health Care Fund 378,528 sh (New)
Joel Greenblatt 59,552 sh (+369.39%)
Paul Tudor Jones Sold Out
Leon Cooperman Sold Out
» More
Q4 2017

BLUE Guru Trades in Q4 2017

Louis Moore Bacon 18,400 sh (New)
Steven Cohen 70,700 sh (New)
Vanguard Health Care Fund 378,528 sh (unchged)
Jim Simons Sold Out
Joel Greenblatt 7,092 sh (-88.09%)
» More
Q1 2018

BLUE Guru Trades in Q1 2018

Pioneer Investments 48,000 sh (New)
Jim Simons 99,800 sh (New)
Louis Moore Bacon Sold Out
Joel Greenblatt 7,054 sh (-0.54%)
Vanguard Health Care Fund 325,428 sh (-14.03%)
Steven Cohen 5,000 sh (-92.93%)
» More
» Details

Insider Trades

Latest Guru Trades with BLUE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2018-03-31 Reduce -14.03%0.02%$163.35 - $233.05 $ 183.10-7%325,428
Joel Greenblatt 2018-03-31 Reduce -0.54%$163.35 - $233.05 $ 183.10-7%7,054
Joel Greenblatt 2017-12-31 Reduce -88.09%0.11%$125.45 - $201.8 $ 183.1017%7,092
Vanguard Health Care Fund 2017-09-30 New Buy0.11%$89.15 - $141.15 $ 183.1071%378,528
Joel Greenblatt 2017-09-30 Add 369.39%0.09%$89.15 - $141.15 $ 183.1071%59,552
Leon Cooperman 2017-09-30 Sold Out 0.22%$89.15 - $141.15 $ 183.1071%0
Leon Cooperman 2017-06-30 New Buy0.22%$75.35 - $120.3 $ 183.1097%50,000
Joel Greenblatt 2017-06-30 New Buy0.02%$75.35 - $120.3 $ 183.1097%12,687
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

bluebird bio Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:JAZZ, NAS:ALKS, NAS:JUNO, HKSE:02269, NAS:SGEN, NAS:BIVV, NAS:NBIX, NAS:BGNE, NAS:SAGE, NAS:EXEL, XKRX:215600, OCSE:GEN, NAS:IONS, TSE:4587, NAS:TECH, HKSE:01530, HKSE:01548, BOM:532523, XKRX:128940, NAS:ALNY » details
Traded in other countries:BLE.Germany,
Headquarter Location:USA
bluebird bio Inc is a clinical-stage biotechnology company which develops gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy.

Bluebird Bio is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.

Top Ranked Articles about bluebird bio Inc

2 Biotech Stocks Move Monday Nektar Therapeutics falls, Bluebird Bio rises
In Monday trading, shares of Nektar Therapeutics Inc. (NASDAQ:NKTR) plummeted after announcing the results of preliminary data from a phase 1/2 clinical trial, called PIVOT, which assesses the combination of NKTR-214 and Bristol-Myers Squibb's (NYSE:BMY) Opdivo (nivolumab) in a range of cancers. The results were presented at the American Society of Clinical Oncology (ASCO) in Chicago. Read more...
Investor Expectations to Drive Momentum within Aerohive Networks, M/I Homes, bluebird bio, Penske Automotive Group, Sanmina, and Genesco — Discovering Underlying Factors of Influence
5 Health Care Stocks Gurus Are Buying These stocks have positions in gurus' portfolios
According to the GuruFocus All-In-One Screener, the following health care stocks are popular among gurus. Read more...
Recent Analysis Shows Forward Industries, Sigma Designs, Northeast, bluebird bio, Walker & Dunlop, and Atmos Energy Market Influences — Renewed Outlook, Key Drivers of Growth
Analysts Take Action on Abbott and Bluebird Bio Abbott Labs receives an upgrade while Bluebird Bio is downgraded
Analysts took action on Abbott (NYSE:ABT) and Bluebird Bio Inc. (NASDAQ:BLUE). Read more...
Is it time to buy stock in bluebird bio Inc., Ford, The Goldman Sachs Group and Juno Therapeutics Inc?
4 Stocks Move to Start the Week Verizon, Celgene, Bluebird Bio rise, Cleantech Solutions falls
Shares of Verizon Communications Inc. (NYSE:VZ) traded higher on news of a $2.25 billion deal with the National Football League. The deal will expand live-streaming of games for all mobile devices, regardless of network. Read more...
Thinking about investing in bluebird bio Inc., Celgene, Gilead Sciences, SunPower or Waste Management?
New Research Coverage Highlights bluebird bio, Accuray, Carlisle Companies, Genesco, Portland General Electric, and Ring Energy — Consolidated Revenues, Company Growth, and Expectations for 2018
New Research Coverage Highlights bluebird bio, Accuray, Carlisle Companies, Genesco, Portland General Electric, and Ring Energy — Consolidated Revenues, Company Growth, and Expectations for 2018

Ratios

vs
industry
vs
history
PB Ratio 5.82
BLUE's PB Ratio is ranked lower than
66% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. BLUE: 5.82 )
Ranked among companies with meaningful PB Ratio only.
BLUE' s PB Ratio Range Over the Past 10 Years
Min: 1.76  Med: 4.03 Max: 13.38
Current: 5.82
1.76
13.38
PS Ratio 185.69
BLUE's PS Ratio is ranked lower than
92% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BLUE: 185.69 )
Ranked among companies with meaningful PS Ratio only.
BLUE' s PS Ratio Range Over the Past 10 Years
Min: 2.52  Med: 155.99 Max: 493.98
Current: 185.69
2.52
493.98
EV-to-EBIT -21.65
BLUE's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. BLUE: -21.65 )
Ranked among companies with meaningful EV-to-EBIT only.
BLUE' s EV-to-EBIT Range Over the Past 10 Years
Min: -80  Med: -13.6 Max: 7.1
Current: -21.65
-80
7.1
EV-to-EBITDA -22.55
BLUE's EV-to-EBITDA is ranked lower than
99.99% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. BLUE: -22.55 )
Ranked among companies with meaningful EV-to-EBITDA only.
BLUE' s EV-to-EBITDA Range Over the Past 10 Years
Min: -86.3  Med: -14.2 Max: 7.2
Current: -22.55
-86.3
7.2
EV-to-Revenue 184.25
BLUE's EV-to-Revenue is ranked lower than
87% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. BLUE: 184.25 )
Ranked among companies with meaningful EV-to-Revenue only.
BLUE' s EV-to-Revenue Range Over the Past 10 Years
Min: -23  Med: 137.05 Max: 412.1
Current: 184.25
-23
412.1
Current Ratio 10.80
BLUE's Current Ratio is ranked higher than
89% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. BLUE: 10.80 )
Ranked among companies with meaningful Current Ratio only.
BLUE' s Current Ratio Range Over the Past 10 Years
Min: 4.55  Med: 9.88 Max: 29.09
Current: 10.8
4.55
29.09
Quick Ratio 10.80
BLUE's Quick Ratio is ranked higher than
89% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. BLUE: 10.80 )
Ranked among companies with meaningful Quick Ratio only.
BLUE' s Quick Ratio Range Over the Past 10 Years
Min: 4.55  Med: 9.88 Max: 29.09
Current: 10.8
4.55
29.09
Days Sales Outstanding 116.71
BLUE's Days Sales Outstanding is ranked higher than
77% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. BLUE: 116.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
BLUE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 32.06  Med: 269.31 Max: 506.55
Current: 116.71
32.06
506.55
Days Payable 3.00
BLUE's Days Payable is ranked lower than
91% of the 456 Companies
in the Global Biotechnology industry.

( Industry Median: 62.86 vs. BLUE: 3.00 )
Ranked among companies with meaningful Days Payable only.
BLUE' s Days Payable Range Over the Past 10 Years
Min: 3  Med: 3077.04 Max: 3077.04
Current: 3
3
3077.04

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -14.90
BLUE's 3-Year Average Share Buyback Ratio is ranked lower than
56% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. BLUE: -14.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BLUE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -545.9  Med: -219.75 Max: -14.9
Current: -14.9
-545.9
-14.9

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 11.11
BLUE's Price-to-Net-Cash is ranked lower than
59% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 8.85 vs. BLUE: 11.11 )
Ranked among companies with meaningful Price-to-Net-Cash only.
BLUE' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.66  Med: 6.59 Max: 14.33
Current: 11.11
3.66
14.33
Price-to-Net-Current-Asset-Value 10.57
BLUE's Price-to-Net-Current-Asset-Value is ranked lower than
64% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. BLUE: 10.57 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BLUE' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.6  Med: 6.47 Max: 14.03
Current: 10.57
3.6
14.03
Price-to-Tangible-Book 5.95
BLUE's Price-to-Tangible-Book is ranked lower than
57% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. BLUE: 5.95 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BLUE' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.04  Med: 4.07 Max: 9.09
Current: 5.95
2.04
9.09
Price-to-Median-PS-Value 1.19
BLUE's Price-to-Median-PS-Value is ranked lower than
77% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. BLUE: 1.19 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BLUE' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.02  Med: 1.01 Max: 2.65
Current: 1.19
0.02
2.65
Earnings Yield (Greenblatt) % -4.65
BLUE's Earnings Yield (Greenblatt) % is ranked higher than
62% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. BLUE: -4.65 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BLUE' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -22.6  Med: -6.6 Max: 15.8
Current: -4.65
-22.6
15.8

More Statistics

Revenue (TTM) (Mil) $44.55
EPS (TTM) $ -8.34
Beta2.83
Volatility57.29%
52-Week Range $85.65 - 236.17
Shares Outstanding (Mil)50.12

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 28 230 659
EBIT (Mil $) -404 -54 467
EBITDA (Mil $) -417 44 485
EPS ($) -9.02 -6.98 -2.18
EPS without NRI ($) -9.02 -6.98 -2.18
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}